PURPOSE: This study aimed to test the influence of functional renal organic cation transporters (OCT2 in humans, Oct1 and Oct2 in mice) on biomarkers of cisplatin nephrotoxicity, such as urinary activity of N-acetyl-beta-D-glucosaminidase (NAG). EXPERIMENTAL DESIGN: Temporal cisplatin-induced nephrotoxicity was assessed by histopathology and biomarkers. Cisplatin-mediated NAG changes and survival were determined in wild-type and Oct1/2(-/-) mice. Identification of OCT2 inhibitors was done in transfected 293Flp-In cells, and the NCI(60) cell line panel was used to assess contribution of OCT2 to cisplatin uptake in cancer cells. RESULTS: Classical biomarkers such as blood urea nitrogen and serum creatinine were not elevated until 72 hours after cisplatin administration and substantial kidney damage had occurred. Oct1/2(-/-) mice had 2.9-fold lower NAG by 4 hours (P < 0.0001) and 2.3-fold increased survival (P = 0.0097). Among 16 agents, cimetidine strongly inhibited uptake of tetraethylammonium bromide (P = 0.0006) and cisplatin (P < 0.0001), but did not have an influence on cisplatin uptake in SK-OV-3 cells, the cancer line with the highest OCT2 mRNA levels. In wild-type mice, cimetidine inhibited cisplatin-induced NAG changes (P = 0.016 versus cisplatin alone) to a degree similar to that seen in Oct1/2(-/-) mice receiving cisplatin (P = 0.91). Cumulative NAG activity of >0.4 absorbance units (AU) was associated with 21-fold increased odds for severe nephrotoxicity (P = 0.0017), which was linked with overall survival (hazard ratio, 8.1; 95% confidence interval, 2.1-31; P = 0.0078). CONCLUSIONS: Cimetidine is able to inhibit OCT2-mediated uptake of cisplatin in the kidney, and subsequently ameliorate nephrotoxicity likely with minimal effect on uptake in tumor cells.
PURPOSE: This study aimed to test the influence of functional renal organic cation transporters (OCT2 in humans, Oct1 and Oct2 in mice) on biomarkers of cisplatinnephrotoxicity, such as urinary activity of N-acetyl-beta-D-glucosaminidase (NAG). EXPERIMENTAL DESIGN: Temporal cisplatin-induced nephrotoxicity was assessed by histopathology and biomarkers. Cisplatin-mediated NAG changes and survival were determined in wild-type and Oct1/2(-/-) mice. Identification of OCT2 inhibitors was done in transfected 293Flp-In cells, and the NCI(60) cell line panel was used to assess contribution of OCT2 to cisplatin uptake in cancer cells. RESULTS: Classical biomarkers such as blood ureanitrogen and serum creatinine were not elevated until 72 hours after cisplatin administration and substantial kidney damage had occurred. Oct1/2(-/-) mice had 2.9-fold lower NAG by 4 hours (P < 0.0001) and 2.3-fold increased survival (P = 0.0097). Among 16 agents, cimetidine strongly inhibited uptake of tetraethylammonium bromide (P = 0.0006) and cisplatin (P < 0.0001), but did not have an influence on cisplatin uptake in SK-OV-3 cells, the cancer line with the highest OCT2 mRNA levels. In wild-type mice, cimetidine inhibited cisplatin-induced NAG changes (P = 0.016 versus cisplatin alone) to a degree similar to that seen in Oct1/2(-/-) mice receiving cisplatin (P = 0.91). Cumulative NAG activity of >0.4 absorbance units (AU) was associated with 21-fold increased odds for severe nephrotoxicity (P = 0.0017), which was linked with overall survival (hazard ratio, 8.1; 95% confidence interval, 2.1-31; P = 0.0078). CONCLUSIONS:Cimetidine is able to inhibit OCT2-mediated uptake of cisplatin in the kidney, and subsequently ameliorate nephrotoxicity likely with minimal effect on uptake in tumor cells.
Authors: Thomas Ludwig; Christoph Riethmüller; Michael Gekle; Gerald Schwerdt; Hans Oberleithner Journal: Kidney Int Date: 2004-07 Impact factor: 10.612
Authors: F E de Jongh; R N van Veen; S J Veltman; R de Wit; M E L van der Burg; M J van den Bent; A S Th Planting; W J Graveland; G Stoter; J Verweij Journal: Br J Cancer Date: 2003-04-22 Impact factor: 7.640
Authors: Dana Ziliak; Peter H O'Donnell; Hae Kyung Im; Eric R Gamazon; Peixian Chen; Shannon Delaney; Sunita Shukla; Soma Das; Nancy J Cox; Everett E Vokes; Ezra E W Cohen; M Eileen Dolan; R Stephanie Huang Journal: Transl Res Date: 2011-02-08 Impact factor: 7.012
Authors: Navjotsingh Pabla; Alice A Gibson; Mike Buege; Su Sien Ong; Lie Li; Shuiying Hu; Guoqing Du; Jason A Sprowl; Aksana Vasilyeva; Laura J Janke; Eberhard Schlatter; Taosheng Chen; Giuliano Ciarimboli; Alex Sparreboom Journal: Proc Natl Acad Sci U S A Date: 2015-04-06 Impact factor: 11.205
Authors: Cynthia S Lancaster; Chaoxin Hu; Ryan M Franke; Kelly K Filipski; Shelley J Orwick; Zhaoyuan Chen; Zhili Zuo; Walter J Loos; Alex Sparreboom Journal: Clin Cancer Res Date: 2010-09-21 Impact factor: 12.531
Authors: Jason A Sprowl; Giuliano Ciarimboli; Cynthia S Lancaster; Hugh Giovinazzo; Alice A Gibson; Guoqing Du; Laura J Janke; Guido Cavaletti; Anthony F Shields; Alex Sparreboom Journal: Proc Natl Acad Sci U S A Date: 2013-06-17 Impact factor: 11.205